To e-mail the previous page to a colleague, simply fill in the required information and click the submit button below. Genentech will not use your information for any purpose other than sending an e-mail to the address you have requested. To learn more about our use of your information, please read our Privacy Policy.

*All fields are required
*Recipient's E-mail: 
*Recipient's Name: 
*Your E-mail: 
*Your Name: 


Content on this page requires a newer version of Adobe® Flash Player.

Get Adobe<sup>®</sup> Flash player

About Lucentis Direc

LUCENTIS Sampling Program

The LUCENTIS Sampling Program is designed to help you:

Start trials on new wet AMD patients or patients with macular edema following RVO to see if LUCENTIS® (ranibizumab injection) is right for them

Treat newly diagnosed wet AMD patients or patients with macular edema following RVO on the same day
Before their next treatment, consider conducting a benefits investigation— LUCENTIS Access Solutions® is here to help

How to Enroll and Request LUCENTIS Samples:
Contact your Clinical Specialist to obtain an Enrollment Request Form Complete it and fax it to 877.329.6737. An email will alert you to log in to your Message Center on LUCENTISDirect.com. Complete and fax the 6-month Sample Request Form. Once you receive a shipment, submit an Acknowledgment of Contents at LUCENTISDirect.com or by mail. Log in to LUCENTISDirect.com to confirm your next shipment. Be sure to confirm or decline each month.

If you do not have a LUCENTIS Direct™ account, you can set up an account here or call one of our Customer Specialists at 800.963.1778.

Samples may not be sold, purchased, traded, returned for credit, or utilized to seek reimbursement. Use of free samples is not contingent on future purchase of commercial LUCENTIS by physicians or patients.


INDICATION

LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with:


  • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  • Macular Edema Following Retinal Vein Occlusion (RVO)

IMPORTANT SAFETY INFORMATION

LUCENTIS is contraindicated in patients with ocular or periocular infections or hypersensitivity to ranibizumab or any of the excipients in LUCENTIS.


WARNINGS AND PRECAUTIONS
Intravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract. Proper aseptic injection technique should always be utilized when administering LUCENTIS. Patients should be monitored during the week following the injection to permit early treatment, should an infection occur.


Increases in intraocular pressure (IOP) have been noted within 60 minutes of intravitreal injection. IOP and perfusion of the optic nerve head should be monitored and managed appropriately.


Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).


ADVERSE EVENTS
Serious adverse events related to the injection procedure occurring in <0.1% of intravitreal injections included endophthalmitis, rhegmatogenous retinal detachment, and iatrogenic traumatic cataract.


In the LUCENTIS Phase III clinical trials, most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, vitreous detachment, maculopathy, and intraocular inflammation. Most common non-ocular side effects included headache, arthralgia, influenza, nasopharyngitis, sinusitis, and bronchitis.


For additional safety information, please see LUCENTIS full prescribing information >>